Synthesis Molecular Modelling and Antibacterial Activity Against Helicobacter pylori of Novel Diflunisal Derivatives as Urease Enzyme Inhibitors

dc.contributor.authorYelekçi, Kemal
dc.contributor.authorDjikic, Teodora
dc.contributor.authorKalaycı, Sadık
dc.contributor.authorYelekçi, Kemal
dc.contributor.authorŞahin, Fikrettin
dc.contributor.authorKüçükgüzel, Şükriye Güniz
dc.date.accessioned2019-06-27T08:02:15Z
dc.date.available2019-06-27T08:02:15Z
dc.date.issued2019
dc.departmentFakülteler, Mühendislik ve Doğa Bilimleri Fakültesi, Biyoinformatik ve Genetik Bölümüen_US
dc.description.abstractBackground: The main factor for the prolongation of the ulcer treatment in the gastrointestinal system would be Helicobacter pylori infection which can possibly lead to gastrointestinal cancer. Triple therapy is the treatment of choice by today's standards. However observed resistance among the bacterial strains can make the situation even worse. Therefore there is a need to discover new targeted antibacterial therapy in order to make success in the eradication of H. pylori infections. Methods: The targeted therapy rule is to identify the related macromolecules that are responsible for the survival of the bacteria. Thus 2-[(2'4'-difluoro-4-hydroxybiphenyl-3-yl)carbonyl]-N-( substituted)hydrazinocarbothioamide (3-13) and 5-(2'4'-difluoro-4-hydroxybiphenyl-3-yl)-4-( substituted)-24-dihydro-3H-124-triazole-3-thiones (14-17) were synthesized and evaluated for antibacterial activity in vitro against H. pylori. Results: All of the tested compounds showed remarkable antibacterial activity compared to the standard drugs (Ornidazole Metronidazole Nitrimidazin and Clarithromycin). Compounds 4 and 13 showed activity as 2 mu g/ml MIC value. Conclusion: In addition we have investigated binding modes and energy of the compounds 4 and 13 on urease enzyme active by using the molecular docking tools.en_US]
dc.identifier.citation5
dc.identifier.doi10.2174/1570180815666180627130208en_US
dc.identifier.endpage400
dc.identifier.issn1570-1808en_US
dc.identifier.issn1875-628Xen_US
dc.identifier.issn1570-1808
dc.identifier.issn1875-628X
dc.identifier.issue4
dc.identifier.scopus2-s2.0-85067207758en_US
dc.identifier.scopusqualityQ3
dc.identifier.startpage392en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12469/582
dc.identifier.urihttps://doi.org/10.2174/1570180815666180627130208
dc.identifier.volume16en_US
dc.identifier.wosWOS:000460607700003en_US
dc.identifier.wosqualityN/A
dc.institutionauthorYelekçi, Kemalen_US
dc.language.isoenen_US
dc.publisherBentham Science Publ Ltden_US
dc.relation.journalLetters in Drug Design & Discoveryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.subjectDiflunisalen_US
dc.subjectHelicobacter pylorien_US
dc.subjectMolecular dockingen_US
dc.subjectThiosemicarbazideen_US
dc.subject124-triazole-3-thionesen_US
dc.subjectMacromoleculesen_US
dc.titleSynthesis Molecular Modelling and Antibacterial Activity Against Helicobacter pylori of Novel Diflunisal Derivatives as Urease Enzyme Inhibitorsen_US
dc.typeArticleen_US
dspace.entity.typePublication
relation.isAuthorOfPublication9407938e-3d31-453b-9199-aaa8280a66c5
relation.isAuthorOfPublication.latestForDiscovery9407938e-3d31-453b-9199-aaa8280a66c5

Files